| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/20/2001 | WO2001068852A2 Apolipoprotein-a-i regulation of t-cell signalling |
| 09/20/2001 | WO2001068851A2 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | WO2001068848A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | WO2001068837A2 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 09/20/2001 | WO2001068815A1 Embryonic stem cells and neural progenitor cells derived therefrom |
| 09/20/2001 | WO2001068698A2 Non-selective cation channel |
| 09/20/2001 | WO2001068697A2 Methods and compositions for immunoregulation |
| 09/20/2001 | WO2001068696A1 Human immune response proteins |
| 09/20/2001 | WO2001068663A1 Nucleoside compounds and uses thereof |
| 09/20/2001 | WO2001068660A1 Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| 09/20/2001 | WO2001068654A2 Tubulin binding ligands and corresponding prodrug constructs |
| 09/20/2001 | WO2001068653A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | WO2001068652A1 Condensed imidazoles as histamine h3 receptor ligands |
| 09/20/2001 | WO2001068651A1 Condensed imidazoles as histamine h3 receptor ligands |
| 09/20/2001 | WO2001068643A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | WO2001068637A2 Method for the preparation of tetrahydrobenzothiepines |
| 09/20/2001 | WO2001068633A1 2-phenylpyran-4-one derivatives |
| 09/20/2001 | WO2001068629A1 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | WO2001068611A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure |
| 09/20/2001 | WO2001068609A1 1,2,3,4-tetrahydroisoquinoline derivatives |
| 09/20/2001 | WO2001068603A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 09/20/2001 | WO2001068597A1 N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them |
| 09/20/2001 | WO2001068592A1 Sulfonamide derivatives |
| 09/20/2001 | WO2001068591A1 Carboxylic acid derivatives as ip antagonists |
| 09/20/2001 | WO2001068582A1 Novel fatty acid analogous |
| 09/20/2001 | WO2001068570A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068569A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068568A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068148A1 Systemic gene delivery vehicles for the treatment of tumors |
| 09/20/2001 | WO2001068146A2 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/20/2001 | WO2001068144A2 Biodegradable immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068142A1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 09/20/2001 | WO2001068135A2 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | WO2001068127A1 Use of growth hormone in low dose |
| 09/20/2001 | WO2001068122A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 09/20/2001 | WO2001068099A1 Modulation of cardiovascular injury |
| 09/20/2001 | WO2001068094A1 Heme oxygenase-1 inducers or induction enhancers |
| 09/20/2001 | WO2001068092A2 Glycogen phosphorylase inhibitor |
| 09/20/2001 | WO2001068078A2 Immunostimulatory polynucleotide sequences for use in suppressing hepatitis virus infection |
| 09/20/2001 | WO2001068077A2 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/20/2001 | WO2001068068A2 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | WO2001068067A2 Use of deramciclane for the treatment of anxiety and depression |
| 09/20/2001 | WO2001068066A2 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| 09/20/2001 | WO2001068065A2 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 09/20/2001 | WO2001068064A2 Use of cdp-choline for the prophylactic treatment of cerebral ischemia |
| 09/20/2001 | WO2001068058A1 Multilayer pharmaceutical product for release in the colon |
| 09/20/2001 | WO2001068055A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001068034A2 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 09/20/2001 | WO2001068033A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001034591A3 Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 09/20/2001 | WO2001029070A8 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 09/20/2001 | WO2001028579A3 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 09/20/2001 | WO2001027110A3 Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring |
| 09/20/2001 | WO2001027109A3 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 09/20/2001 | WO2001016358A3 Method of screening for triacyglycerol hydrolase inhibitors |
| 09/20/2001 | WO2001016165A3 Apoptin-associating protein |
| 09/20/2001 | WO2001015664A3 Coformulation methods and their products |
| 09/20/2001 | WO2001013953A3 Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist |
| 09/20/2001 | WO2001010427A3 Use of anti-muscarinic agents for treating skin disorders |
| 09/20/2001 | WO2001007065B1 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 09/20/2001 | WO2001002540A9 Adenoviral vectors for treating disease |
| 09/20/2001 | WO2000071506A9 Naphthalene ureas as glucose uptake enhancers |
| 09/20/2001 | WO2000047583A9 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 09/20/2001 | WO2000047553A8 ALKENYL AND ALKYNYL COMPOUNDS AS INHIBITORS OF FACTOR Xa |
| 09/20/2001 | WO2000044774A9 Inhibition of stat3 signal transduction for human cancer therapy |
| 09/20/2001 | WO2000027378A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | WO2000018899A3 Angiotensin converting enzyme homolog and its use |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023349 Hypodermic needle with weeping tip and method of use |
| 09/20/2001 | US20010023292 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example |
| 09/20/2001 | US20010023291 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| 09/20/2001 | US20010023253 Novel compound |
| 09/20/2001 | US20010023250 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 09/20/2001 | US20010023244 Thrombin inhibitors |
| 09/20/2001 | US20010023061 Assaying the effect of test tumor cell modulation |
| 09/20/2001 | US20010022978 Therapy for sensitive skin |
| 09/20/2001 | US20010022970 Halogenated xanthan compound |
| 09/20/2001 | EP1143960A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | DE10013296A1 New nucleic acid encoding the non-selective cation channel OTRPC4, useful for treating osmolality-associated disorders, e.g. diabetes comprises the modulation of activity |
| 09/20/2001 | DE10013029A1 Multilayer formulation for controlled drug release in colon, comprising drug-containing core having inner and outer coatings of acrylic copolymers with quaternary ammonium and anionic groups respectively |
| 09/20/2001 | CA2403679A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403420A1 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403350A1 Use of deramciclane for the treatment of anxiety and depression |
| 09/20/2001 | CA2403241A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | CA2403233A1 Glycogen phosphorylase inhibitor |
| 09/20/2001 | CA2403188A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure |
| 09/20/2001 | CA2403149A1 2-phenylpyran-4-one derivatives |
| 09/20/2001 | CA2403084A1 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" |
| 09/20/2001 | CA2403000A1 Embryonic stem cells and neural progenitor cells derived therefrom |
| 09/20/2001 | CA2402948A1 Use of growth hormone in low dose |
| 09/20/2001 | CA2402908A1 Assay for agents that induce chemokinesis |
| 09/20/2001 | CA2402898A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | CA2402891A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2402772A1 Apolipoprotein-a-i regulation of t-cell signalling |
| 09/20/2001 | CA2402729A1 Human immune response proteins |
| 09/20/2001 | CA2402645A1 Modulation of cardiovascular injury |
| 09/20/2001 | CA2402553A1 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | CA2402549A1 Substituted beta-carbolines |